You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 12, 2025

Claims for Patent: 4,738,974

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,738,974

Title:	Base addition salts of omeprazole
Abstract:	Novel salts of omeprazole with Li.sup.+, Na.sup.+, K.sup.+, Mg.sup.2+, Ca.sup.2+, Ti.sup.4+, N.sup.+ (R.sup.1).sub.4 or ##STR1## as cation; processes for their preparation thereof, pharmaceutical compositions containing such salts and their use in medicine.
Inventor(s):	Brandstrom; Arne E. (Gothenburg, SE)
Assignee:	Aktiebolaget Hassle (SE)
Application Number:	06/854,739
Patent Claims:	1. A compound of the formula ##STR9## wherein n is 1, 2, or 4; and A.sup.n+ is Li.sup.+, Na.sup.+, K.sup.+, Mg.sup.2+, or Ca.sup.2+. 2. A compound according to claim 1 wherein A.sup.n+ is Na.sup.+, K.sup.+, Mg.sup.2+ or Ca.sup.2+. 3. A compound according to claim 1 wherein A.sup.n+ is Na.sup.+. 4. A compound according to claim 1 wherein A.sup.n+ is Mg.sup.2+. 5. A pharmaceutical composition for inhibiting gastric acid secretion comprising a compound according to claim 1 in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition for inhibiting gastric acid secretion comprising a compound according to claim 2 in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. 7. A pharmaceutical composition for inhibiting gastric acid secretion comprising a compound according to claim 3 in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. 8. A pharmaceutical composition for inhibiting gastric acid secretion comprising a compound according to claim 4 in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. 9. A method for inhibiting gastric acid secretion by administering to mammals an amount of a compound as defined in claim 1 sufficient to inhibit gastric acid secretion. 10. A method for inhibiting gastric acid secretion by administering to mammals an amount of a compound as defined in claim 2 sufficient to inhibit gastric acid secretion. 11. A method for inhibiting gastric acid secretion by administering to mammals an amount of a compound as defined in claim 3 sufficient to inhibit gastric acid secretion. 12. A method for inhibiting gastric acid secretion by administering to mammals an amount of a compound as defined in claim 4 sufficient to inhibit gastric acid secretion. 13. A method for the treatment of gastrointestinal inflammatory diseases in mammals by administering to mammals an amount of a compound as defined in claim 1 sufficient to treat gastrointestinal inflammatory disease. 14. A method for the treatment of gastrointestinal inflammatory diseases in mammals by administering to mammals an amount of a compound as defined in claim 2 sufficient to treat gastrointestinal inflammatory disease. 15. A method for the treatment of gastrointestinal inflammatory diseases in mammals by administering to mammals an amount of a compound as defined in claim 3 sufficient to treat gastrointestinal inflammatory disease. 16. A method for the treatment of gastrointestinal inflammatory diseases in mammals by administering to mammals an amount of a compound as defined in claim 4 sufficient to treat gastrointestinal inflammatory disease. 17. A method for providing gastrointestinal cytoprotective effects in mammals by administering to mammals an amount of a compound as defined in claim 1 sufficient to provide gastrointestinal cytoprotective effects. 18. A method for providing gastrointestinal cytoprotective effects in mammals by administering to mammals an amount of a compound as defined in claim 2 sufficient to provide gastrointestinal cytoprotective effects. 19. A method for providing gastrointestinal cytoprotective effects in mammals by administering to mammals an amount of a compound as defined in claim 3 sufficient to provide gastrointestinal cytoprotective effects. 20. A method for providing gastrointestinal cytoprotective effects in mammals by administering to mammals an amount of a compound as defined in claim 4 sufficient to provide gastrointestinal cytoprotective effects.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.